Study or Subgroup	Nicorandil Events	Nicorandil Total	Control Events	Control Total	Weight	Odds Ratio M-H, Random, 95% CI
1.9.1 no nicorandil after PPCI						
Chen 2015	2	52	4	52	4.7%	0.48 [0.08, 2.74]
Feng 2019	6	90	16	90	9.4%	0.33 [0.12, 0.89]
Ishii 2005	47	185	66	183	15.3%	0.60 [0.39, 0.94]
Lee 2008	2	37	2	36	3.8%	0.97 [0.13, 7.29]
Ota 2006a	4	32	9	27	6.9%	0.29 [0.08, 1.07]
Pi 2019a	29	47	38	45	9.4%	0.30 [0.11, 0.81]
Qi 2018	1	40	12	80	3.6%	0.15 [0.02, 1.16]
Subtotal (95% CI)		**483**		**513**	**53.0%**	**0.47 [0.33, 0.67]**
Total events	91		147			
Heterogeneity: Tau² = 0.00; Chi² = 4.81, df = 6 (P = 0.57); I² = 0%						
Test for overall effect: Z = 4.25 (P < 0.0001)						
1.9.2 maintaining nicorandil after PPCI						
Chen 2020	6	39	13	39	8.5%	0.36 [0.12, 1.09]
Kitakaze 2007	55	276	58	269	15.6%	0.91 [0.60, 1.37]
Ono 2004	5	33	10	25	7.4%	0.27 [0.08, 0.93]
Ota 2006b	3	31	9	27	6.2%	0.21 [0.05, 0.90]
Pi 2019b	17	48	38	45	9.3%	0.10 [0.04, 0.27]
Subtotal (95% CI)		**427**		**405**	**47.0%**	**0.30 [0.12, 0.79]**
Total events	86		128			
Heterogeneity: Tau² = 0.90; Chi² = 20.13, df = 4 (P = 0.0005); I² = 80%						
Test for overall effect: Z = 2.44 (P = 0.01)						
Total (95% CI)		**910**		**918**	**100.0%**	**0.37 [0.24, 0.57]**
Total events	177		275			
Heterogeneity: Tau² = 0.28; Chi² = 25.27, df = 11 (P = 0.008); I² = 56%						
Test for overall effect: Z = 4.44 (P < 0.00001)						
Test for subgroup differences: Chi² = 0.72, df = 1 (P = 0.40), I² = 0%